Cspc Pharmaceutical Group Limited · HKEX:1093
Cspc Pharmaceutical — FY2025 Earnings Presentation
30 slides from Cspc Pharmaceutical's earnings presentation, March 2026
Slide 1: CSPC 2025 Results Presentation
NoxBseRoaa CSPC CSPC PHARMACEUTICAL GROUP LIMITED (Stock Code : 1093) 2025 Results Presentation Mar. 2026
Slide 2: 2025 Updates
Fr 2025 Updates || Regulatory Updates Fi) F New drugs approved (including new indications): + Enyitan + Duoenyi - 1L Pancreatic cancer + Shanzeping + Clevidipine injectable emulsion + Meiluotai Breakthrough Therapy Designations: * SYS6010 (EGFR ADC) - NSCLC * Sirolimus for injection (aloumin-bound)
Slide 3: Business Development Drives Global Expansion
[my Business Development Drives Global Expansion In 2025, 4 BD transactions have been completed. os q 7 . - ” ©) 18.5 billion US dollars — The largest-ever licensing The total licence fee is 9.71 billion US dollars , including 260 milion US dollars upfront payment. deal by a Chinese pharmaceutical c
Slide 4: 2025 Clinical Progress - With High Efficiency
[my 2025 Clinical Progress - With High Efficiency —— JMT106 ‘sYs6040 SYS6036 ‘SYS6043 Sirolimus for injection Anbenitamab repodatecan —_Anbenitamab Pertuzumab GPC3/IFNBsAb —DLL3 ADC Biosimilar B7H3 ADC (albumin-bound) (JSKNO03) injection (KNO26) —_Breast cancer ‘Advanced solid Advanced solid tumors
Slide 5: 2026 Data Read-out Plan
[gy 2026 Data Read-out Plan —— = (’) Phase I/II Data Read-out ‘oy Pivotal Trial Data Read-out SYS6010 SYS6043 SYS6043 © sys6o10 AACR EGFR ADC ICHNO B7H3 ADC sGo B7H3 ADC In plan EGFR ADC accepted N. accepted accepted , jasopharyngeal Nasopharyngeal Gynecological tumor - phase | - 2L EGFRmut NSCLC -
Slide 6: Financial Highlights
Financial Highlights
Slide 7: Financial Highlights
[my Financial Highlights Unit: RMB’ M 2025 2024 Change Revenue 26,006 29,009 -10.4% Gross profit 17,059 20,299 -16.0% Gross profit margin 65.6% 70.0% -4.4 pp R&D expenses 5,809 5,191 +11.9% Reported profit attributable to shareholders of the Company 3,882 4,328 -10.3% Underlying profit attributable
Slide 8: Revenue
ir Revenue = a Revenue by product category Revenue by therapeutic area Unit: RMB’ M 2025 2024 Change Chi ps ce mead Nervous system 7,817 9,645 -19.0% H Oncology 2,201 4,400 -50.0% 1 ——————— r Anti-infectives 3,324 4,086 -18.7% Bulk vitamin C 2,231 1,994 +11.9% Cardiovascular 1,834 2,079 -11.8% Respi
Slide 9: Operating Profit
Operating Profit Unit: RMB’ M 2025 2024 2025 2024 Change ear] on Change Finished drugs 3,871 4,828 -19.8% 18.8% 20.3% -1.5 pp Bulk vitamin C 192 211 -9.2% 8.6% 10.6% -2.0 pp Bulk antibiotics 184 299 -38.4% 12.9% 18.8% -5.9 pp Functional Food and Others 276 305 -9.6% 15.6% 18.1% -2.5 pp 1 Note: Certa
Slide 10: R&D Pipeline
R&D Pipeline
Slide 11: R&D Overview
[gy R&D Overview R&D Centers & Projects Technology Platforms + 5 R&D centres located in + 8 national science & technology China & the U.S. qualifications + Approx. 200 Innovative drugs + 2national key labs and new formulations + 8 innovative R&D platforms Intellectual Property + 2666 patent applicat
Slide 12: Major R&D Technology Platforms
8 Major R&D Technology Platforms Nanoparticle Formulation Technology Platform >» Mitoxantrone hydrochloride liposomes > Docetaxel for injection (albumin-bound) > lrinotecan liposomes > Sirolimus for injection (albumin-bound) Antibody/Fusion Protein Technology Platform ‘ea ie > JMT203 (GFRAL) > JMT10
Slide 13: Expected Launch 2026-2028 (In plan)
Expected Launch 2026-2028 (In plan) Si) M1 has completed Launched 2021-2025 Anfulike Duoenda Duentai Jinlitai Mingfule (AIS) Enyitan Enshuxing Ansulike Meiluotai \ Shanzeping J Expected Launch 2026 (In plan) Clevidipine Injectable Emulsion Acute hypertension crisis Va Anbenitamab Injection (KNO26) H
Slide 14: Positive results for JMT101 in Phase II trial for colorectal cancer
rr Positive results for JMT101 in Phase II trial for colorectal cancer===== Results of a randomized, controlled, open-label Phase Il trial for the treatment of advanced colorectal cancer (3L+) ASCO 101 + irinotecan + S (Arm A, n=36) (Arm B, n=35) (Arm C, n=35) Events, 18 20 28 n/N (%) (50.0) (57.1)
Slide 15: Positive results for Anbenitamab in Phase III Gastric Cancer Trial
ir Positive results for Anbenitamab in Phase Ill Gastric Cancer Tria congress yl HER2 + Gastric cancer(2L+) interim analysis results of Phase Ill trial Main results: > PFS: 7.1 vs 2.7 mo OS: 19.6 vs 11.5 mo HR 0.25 HR 0.29 % ORR: 56% vs 11% 3X Grade 23TRAEs 60% vs 45% IRC-assessed PFS: primary endpo
Slide 16: Preclinical data announced for multiple candidates
Li Preclinical data announced for multiple candidates "= aobesityweek | O November 4-7, 2025 « Atlanta JMT206 Best-In-Class ACTRIIA/IIB Blocker For Superior Body Composition Management In Combination With GLP-1 RAs ID: Poster-467 CSPC-ALK7— a ALK7 siRNA CCSPC-ALK7, a ALKT SIRNA Demonstrates Efficacy
Slide 17: R&D pipeline — Vaccine, CAR-T
[my R&D pipeline — Vaccine, CAR-T = Premier mRNA Delivery Platform The world's first LNP ex vivo CAR-T with clinical approval, and China’s first in vivo CAR-T granted clinical IND. Va mRNA ~\ Preventive — Therapeutic vaccine In vivo CAR-T caniiletes Target Type Phase | Phase Il Phase lll Launch stra
Slide 18: R&D pipeline - siRNA Series Products
[gy R&D pipeline - SIRNA Series Products = 5 products have advanced to the clinical stage, with both the number and progress of pipelines ranking first in China. Targeted delivery to the eyes, lungs, fat, and muscles has been achieved, enabling a broader range of indications. Major HE candidates Tar
Slide 19: R&D Pipeline - Biological Agents
° . ° ° | [gy R&D Pipeline - Biological Agents —— 3 commercialized, 6 BLA filed, 7 under pivotal trial stage -- Including various forms of drugs such as antibody drugs, cell therapies, and Antibody-Drug Conjugates (ADCs) Major candidates Target Type Phase I Phase II Phase Ill NDA/BLA Launch Omalizum
Slide 20: R&D Pipeline — Biological Agents
R&D Pipeline — Biological Agents aha Target Type Phase | Phase II Phase Ill NDA/BLA Launch JMT103 RANKL mAb Launch: GCTB; Under clinical development: bone metastasis (Phill). osteoporosis oe HER2 BsAb 2L Gastric cancer (BLA), 1L Breast cancer (Phill), Adjuvant therapy for BC (Phill) Pertuzumab HER2
Slide 21: R&D Pipeline - New Formulations
° . e | R&D Pipeline - New Formulations — 4 commercialized, 3 NDA filed, 3 under pivotal trial stage -- Including various forms of drugs such as liposomes, albumin and nanocrystals Major candidates Type Phase | Phase II Phase Ill NDA/IBLA Launch oe a ete ene Launch: PTCL; Under clinical development:
Slide 22: R&D Pipeline - Small Molecule Drugs
[gy R&D Pipeline - Small Molecule Drugs — 1 commercialized, 1 NDA filed, 6 under pivotal trial stage Major candidates Target Type Phase | Phase Il Phase Ill NDA/BLA Launch SYHA1813 VEGFR/CSF1R Small molecule Advanced meningioma, Consolidation therapy for SCLC Oncology SYH2043 CDK2/4/6 Small molecule
Slide 23: Common Generics Launch Plan
r Common Generics Launch Plan 20+ generic drugs are expected to be launched during the years 2025-2026; Additionally, approximately 30 projects are currently in the pharmaceutical research phase. Peramivir Injection Regorafenib tablets Alprazole enteric a A i | I ic- Tandospirone citrate lansoprazol
Slide 24: ESG
ESG
Slide 25: Aim to Become an ESG Leader in Pharmaceutical Industry
[gy Aim to Become an ESG Leader in Pharmaceutical Industry==—= 2024 Key Environmental Protection Data Received MSCI ESG Rating of A for 5 *The emission reduction target is based on the emission in 2017 consecutive years Emission of non-hazardous Greenhouse gas emissions per waste (general solid wast
Slide 26: Appendix: Product Overview
Appendix: Product Overview
Slide 27: R&D Capabilities
R&D Capabilities Manufacturing Capabilities 10+ Production bases for pharmaceutical products Nano formulation production capacity of 20M doses/year; Biologics fermentation capacity of 250,000L Chemical drugs production capacity of OSD ~30B tablets/year, production capacity of injection ~3B doses/yea
Slide 28: Finished Drugs Overview by Therapeutic Areas
Ly Finished Drugs Overview by Therapeutic Areas Others Digestion & 7.73% metabolism / 5.01% \ Respiratory system — y 6.51% 2025 Total : 18.795 B (excluding licence fee income) a Cardio- vascular 9.76% Anti-infective \ 17.69% Oncology 11.71% Nervous system 41.59% y Nervous system Oncology Anti- infec
Slide 29: Innovation achievements: Overview of Key products
Innovation achievements: Overview of Key products === New Formulations and Innovative drugs Biosimilar Drugs FOO IIA lalate aaa atta 2 Sond at III IOS ISOS OSIIIOSS Q, _ jewoeooecsssscscccosssasssEssscsaesasssacss ~, als N E's (Se. E.= ID = Jinyouli x = - Cs : Butyl phthalide Recombinant human TNK P
Slide 30: E-mail Address of CSPC IR Team
E-mail Address of CSPC IR Team: ir@cspc.cn SUPPORT GUIDANCE 7 IR official website: “EaRyGA
CSPC Pharmaceutical Group — FY2025 Earnings Presentation on 6ix